To address the role of S1PR2 during the early phases of tumor development, we inhibited pharmacologically S1PR2 in ApcMin/+ mice at 10 weeks of age, before the appearance of both intestinal and colonic tumors, by the specific S1PR2 inhibitor (JTE013). Here, S1PR2 is linked to neoplasm.